The respective BRAF resistant cell lines (A375R, WM9R, WM35R and WM902BR (Supplementary Figure S1), as well as BRAF wildtype melanoma cell lines (MV3, SK-Mel30) and normal human epidermal melanocytes (NHEM) showed no significant change in miR-129-5p expression after Vemurafenib treatment (Figure 1C). The gene discussed is BRAF; the disease is melanoma.